anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Glomerulonephritis (GN) after kidney transplantation is a common problem. Many of them are recurrences of the primary disease in the transplanted kidney. The course and prognosis of individual types of glomerulonephritis (GN) are very different and their appearance may worsen the graft survival. World statistics show significant discrepancies regarding the incidence of GN recurrence depending on the adopted protocol (protocolar biopsy or due to symptoms). We analyzed the transplanted kidney biopsy results that are performed only in symptomatic patients.
METHODS: A group of 125 patients transplanted and treated in one medical center were observed. In this group, in 32 patients, the primary kidney disease was GN, confirmed by kidney biopsy before transplantation. Twenty three kidney biopsies were performed; in 8, cases the primary disease was GN. The indication for biopsy were hematuria and/or proteinuria and/or graft failure.
RESULTS: We diagnosed 5 cases of GN, including 4 cases of GN recurrence (12.5% in whole GN group, 50% in symptomatic GN group). In the relapse group, there was 1 case of IgA nephropathy (the earliest recurrence 1 month after transplantation), 1 case of focal segmental glomerulosclerosis, 1 case of membranous nephropathy, and 1 case of lupus nephritis (the latest recurrence 1 year and 4 months after transplantation).
CONCLUSIONS: Our observation showed a high percentage of GN recurrences in symptomatic patients. This indicates the need to specify data regarding the diagnosis of recurrence depending on the adopted research method (protocolar or due to symptoms biopsy) to know which patients should be treated.
<P>PROBLEM TO BE SOLVED: To provide a muscle damage inhibitory composition high in safety and even higher in muscle damage inhibitory effect.  <P>SOLUTION: The muscle damage inhibitory composition contains, as active ingredient, a liposoluble organic solvent extract of acetic acid bacteria, preferably an ethyl acetate extract of acetic acid bacteria. Specifically, the above extract is acetic acid bacteria alkali-stabilized lipids. More specifically, the above lipids is an N-acylsphinganine, sphinganine, aminolipids or a terpenoid compound. Another version of this composition contains, as active ingredient, a liposoluble organic solvent extract of vinegar, preferably an ethyl acetate extract of vinegar.  <P>COPYRIGHT: (C)2007,JPO&INPIT
A PRP separator-concentrator comprising a housing, a separation assembly, and a concentration assembly. The concentration assembly has a concentration sump. An axially concentric rigid stationary outlet tube is secured to the housing and extends through the separation assembly to the sump. The separation assembly is attached to and positioned above the concentration assembly to form a combined separator-concentrator assemblage that is rotatable about the outlet tube. The separation assembly includes a separation chamber lined with a depth filter having pores and passageways that are sized to receive and entrap erythrocytes during centrifuging. The concentration chamber has a floor for supporting desiccated beads and a wall with at least one opening closed with a screen. The concentrator can have a distribution of upright screen supports, the upright screen supports having an inner surface and an outer surface, the cylindrical screen being supported on the outer surface of the upright screen supports. A stationary bead rake can be secured to the stationary tube and extend outward therefrom, the rake having distal ends that are spaced at a distance from the upright screen supports. The rake can comprise a longitudinal body, the center of which is secured to the rigid outlet tube. The separator-concentrator includes a valve assembly connecting the separation chamber and the concentration chamber. PRP concentrate is produced by contacting PRP with desiccated beads while the beads are stirred with a stationary rake, and rotating the concentration chamber at centrifugal speeds to separate PRP concentrate from the beads.
Subjects randomized to the eUC + Peer support intervention will be matched with a peer coach of the same gender, race, and approximate age. For those enrolled during a hospitalization, coaches will be instructed to attempt the initial phone contact prior to the patient's discharge; for patients enrolled after an ED visit or outpatient exacerbation, coaches will be instructed to contact the patients within 72 hours of randomization. Peer coaches will be asked to complete at least one call each week during months 1-2, biweekly calls during months 3-4, and monthly calls during months 5-6. Coaches will be asked to follow a conversation guide, provided during the initial training, to structure phone conversations with their paired patient.
OBJECTIVE: The relationship between low income and adverse perinatal outcomes, such as low birth weight and developmental delays, is well established making the search for protective factors important. One such factor may be neighbourhood greenspace. This study elucidates the role of urban neighbourhood greenspace in the relationship between income and perinatal outcomes in a nationally representative birth cohort from the UK.
METHODS: Data on 14 050 infants participating in the initial wave at age 9 months of the Millennium Cohort Study were used (51% male, 20% non-white, 52% living in disadvantaged areas). We tested whether the association between income and perinatal outcomes is moderated by urban greenspace (measured in deciles) before and after adjustments for confounding. The perinatal outcomes included birth weight, gestational age (in days), communication and motor delays. The models were adjusted for the infant's sex and ethnicity, mother's age, education, substance use and mental health as well as area disadvantage and air pollution.
RESULTS: Neighbourhood greenspace moderated the association between income and gestational age, even after adjustment for all confounders, b=-0.11, 95% CI (-0.215, -0.004). For births in low-income households, in particular, it was associated with an increase in gestational age by an average of approximately 3 days. However, after adjustment, greenspace was not found to influence birth weight, communication or motor delays at age 9 months.
CONCLUSION: The biophilic design of urban environments is a modifiable factor for improving perinatal outcomes in the UK as urban greenspaces appear to be mitigating the risk of preterm birth associated with family poverty.
Using a seamless, adaptive, phase II/III design, the investigators will determine the safety and efficacy of arimoclomol in patients with SOD1 positive familial ALS. Both stage-1 and stage-2 are randomized, double-blind and placebo-controlled in a population of patients with rapidly progressive SOD1 positive familial ALS. Patients with ALS, a history of a relative affected with ALS (i.e. familial ALS) and the presence of a demonstrable mutation in the SOD1 gene that is known to be associated with rapidly progressive disease, will be eligible for inclusion in this study. Potentially eligible subjects will undergo screening via telephone and, if necessary, review of outside medical records. The intervention will continue for up to 12 months. In the event that a participant reaches a study endpoint (e.g. tracheostomy or permanently assisted ventilation) study drug will be terminated. Subjects who meet all eligibility criteria will travel a study site for final eligibility determination, baseline evaluation and will then be randomized 1:1 to receive either placebo or arimoclomol at a dose of 200 mg t.i.d. Participants will then be evaluated again in person at a study site at Month-2. Telephonic evaluations at Month-1, 3, 4, 5, 6, 8, and 10 will be performed in participants' homes. Safety and tolerability evaluations will be performed at each of these visits. Collection of blood samples for safety laboratory analyses and measurement of blood pressure, heart rate, respiratory rate, temperature and weight will be performed at Months-1, 3, 4, 5, 6, 8, and 10 in the participant's home by a representative of a medical monitoring company. A study coordinator may perform an in-person visit at Month-12, or this visit may occur telephonically. A final evaluation will be performed via telephone at Month-13 (30 days after the last dose of study medication).
PURPOSE:To provide a new beta-alanine derivative useful as a raw material for introducing polyamine into amino acids, peptides, and amine compounds, or a raw material for glutamic acid blocking agents. CONSTITUTION:The objective new beta-alanine derivative of formula I (R1 is alkyl, aryl or aralkyl; Boc is t-butyloxycarbonyl; m is an integer of 1-10), e.g. a compound of formula II. The compound of the formula I can be obtained by reaction of a compound of formula III (R2 is alkylsulfonyl, arylsulfonyl or aralkylsulfonyl) with an alkali azide. The compound of the formula III can be obtained by the following process: a compound of formula IV is made to react with a t- butyloxycarbonylating reagent to form a compound of formula V, which is, in turn, made to react with an alkali borohydride to produce a compound of formula VI, which is then made to react with a compound of formula R2X (X is halogen). The other objective glutamic acid blocking agent can be obtained from the compound of the formula I.
Tumor cell invasion is considered as one of the main therapeutic challenges in cancer patients, which leads to distant metastasis and reduced prognosis. Therefore, investigation of the factors involved in tumor cell invasion improves the therapeutic methods to reduce tumor metastasis. Epithelial-mesenchymal transition (EMT) process has a pivotal role in tumor cell invasion and metastasis, during which tumor cells gain the invasive ability by losing epithelial characteristics and acquiring mesenchymal characteristics. WNT/β-catenin signaling pathway has a key role in tumor cell invasion by regulation of EMT process. Long non-coding RNAs (lncRNAs) have also an important role in EMT process through the regulation of WNT/β-catenin pathway. Deregulation of lncRNAs is associated with tumor metastasis in different tumor types. Therefore, in the present review, we investigated the role of lncRNAs in EMT process and tumor cell invasion through the regulation of WNT/β-catenin pathway. It has been reported that lncRNAs mainly induced the EMT process and tumor cell invasion through the activation of WNT/β-catenin pathway. LncRNAs that regulate the WNT/β-catenin mediated EMT process can be introduced as the prognostic markers as well as suitable therapeutic targets to reduce the tumor metastasis in cancer patients.
BACKGROUND: Energy-dissipating brown adipocytes have significant potential for improving systemic metabolism. Vanin-1, a membrane-bound pantetheinase, is involved in various biological processes in mice. However, its role in BAT mitochondrial function is still unclear. In this study, we aimed to elucidate the impact of Vanin-1 on BAT function and contribution during overnutrition-induced obesity.
METHODS: Vanin-1 expression was analyzed in different adipose depots in mice. The cellular localization of Vanin-1 was analyzed by confocal microscopy and western blots. Mice lacking Vanin-1 (Vanin-1-/-) were continuously fed either a chow diet or a high-fat diet (HFD) to establish an obesity model. RNA-seq analysis was performed to identify the molecular changes associated with Vanin-1 deficiency during obesity. BAT-specific Vanin-1 overexpression mice were established to determine the effects of Vanin-1 in vivo. Cysteamine treatment was used to examine the effect of enzymatic reaction products of Vanin-1 on BAT mitochondria function in Vanin-1-/- mice.
RESULTS: The results indicate that the expression of Vanin-1 is reduced in BAT from both diet-induced and leptin-deficient obese mice. Study on the subcellular location of Vanin-1 shows that it has a mitochondrial localization. Vanin-1 deficiency results in increased adiposity, BAT dysfunction, aberrant mitochondrial structure, and promotes HFD induced-BAT whitening. This is attributed to the impairment of the electron transport chain (ETC) in mitochondria due to Vanin-1 deficiency, resulting in reduced mitochondrial respiration. Overexpression of Vanin-1 significantly enhances energy expenditure and thermogenesis in BAT, renders mice resistant to diet-induced obesity. Furthermore, treatment with cysteamine rescue the mitochondrial dysfunction in Vanin-1-/- mice.
CONCLUSIONS: Collectively, these findings suggest that Vanin-1 plays a crucial role in promoting mitochondrial respiration to counteract diet-induced obesity, making it a potential therapeutic target for obesity.
ZOHYDRO ER is contraindicated in patients with known or suspected paralytic ileus. Opioids diminish propulsive peristaltic waves in the gastrointestinal tract and decrease bowel motility. Monitor for decreased bowel motility in post-operative patients receiving opioids. The administration of ZOHYDRO ER may obscure the diagnosis or clinical course in patients with acute abdominal conditions. Hydrocodone may cause spasm of the sphincter of Oddi. Monitor patients with biliary tract disease, including acute pancreatitis.
Regular nursing visit: 1. Explanation of the meaning of a positive result in the FIT. 2. Explanation of the need to perform a colonoscopy with sedation. 3. Anamnesis. 4. Agreement of the day and hour to perform the colonoscopy. 5. Explanation of the diet and delivery of preparation for the preparation of the colon.
ETHNOPHARMACOLOGICAL RELEVANCE: Plants and fungi have a long tradition in ethnopharmacology for the treatment of infectious diseases including viruses. Many of these natural products have also been used to combat SARS-CoV-2 infections or symptoms of the post- and long-COVID form, owing to the scarcity of clinically approved therapeutics.
AIM OF THE STUDY: The ongoing threat posed by SARS-CoV-2, along with the rapidly evolving new variants, requires the development of new antiviral compounds. The aim of this study was to identify anti-SARS-CoV-2 herbal and fungal extracts used in traditional medicine against acute respiratory infection, inflammation, and related symptoms. Additionally, we sought to characterize their bioactive constituents.
MATERIALS AND METHODS: The antiviral activity and cell cytotoxicity of 179 herbal and fungal extracts were evaluated using two SARS-CoV-2 infection assays in Caco-2 cells. 19 plant extracts with and without anti-SARS-CoV-2 activity underwent detailed dereplication using molecular networking.
RESULTS: Extracts from Angelica sinensis (Oliv.) Diels roots, Annona squamosa L. seeds, Azadirachta indica A. Juss. fruits, Buddleja officinalis Maxim. flowers, Burkea africana Hook. bark and Clinopodium menthifolium (Host) Stace aerial parts showed a potent anti SARS-CoV-2 activity (IC50 < 5 μg/ml) with only moderate cytotoxicity (CC50 > 60 μg/ml, Caco-2). By performing the dereplication with a bioactivity-featured molecular network (MN) on the extract library level, rather than on the level of individual extracts, we could pinpoint compounds characteristic for active extracts. Thus, a straight-forward identification of potential anti-SARS-CoV-2 natural compounds was achieved prior to any fractionation or isolation efforts.
CONCLUSIONS: A sophisticated hyphenation of empirical knowledge with MS-based bioinformatics and automated compound annotation was applied to decipher the chemical space of the investigated extracts. The correlation with experimentally assessed anti-SARS-CoV-2 activities helped in predicting compound classes and structural elements relevant for the antiviral activities. Consequently, this accelerated the identification of constituents from the investigated mixtures with inhibitory effects against SARS-CoV-2.
Astronauts on 2-month International Space Station missions will be exposed to spaceflight for a duration of 2 months. Biometric and cognitive data will routinely be collected.
PURPOSE: An anti-obesity composition using a Sargassum muticum extract is provided to be used as an anti-obesity composition, a hyperlipidemia treatment composition, and a fatty acid treatment composition and to manufacture foods or pharmaceutical products. CONSTITUTION: An anti-obesity composition contains a Sargassum muticum extract as an active ingredient. The extract is prepared using water, ethanol, or a mixture thereof. A hyperlipidemia treatment composition contains the extract as an active ingredient. A fatty liver treatment composition contains the extract as an active ingredient. A diet composition contains the extract as an active ingredient.
The transcriptional response to hypoxia is temporally regulated, yet the molecular underpinnings and physiological implications are unknown. We examined the roles of hepatic Bmal1 and Hif1α in the circadian response to hypoxia in mice. We found that the majority of the transcriptional response to hypoxia is dependent on either Bmal1 or Hif1α, through shared and distinct roles that are daytime determined. We further show that hypoxia-inducible factor (HIF)1α accumulation upon hypoxia is temporally regulated and Bmal1 dependent. Unexpectedly, mice lacking both hepatic Bmal1 and Hif1α are hypoxemic and exhibit increased mortality upon hypoxic exposure in a daytime-dependent manner. These mice display mild liver dysfunction with pulmonary vasodilation likely due to extracellular signaling regulated kinase (ERK) activation, endothelial nitric oxide synthase, and nitric oxide accumulation in lungs, suggestive of hepatopulmonary syndrome. Our findings indicate that hepatic BMAL1 and HIF1α are key time-dependent regulators of the hypoxic response and can provide molecular insights into the pathophysiology of hepatopulmonary syndrome.
Note: 37.5 mg/25 mg = 37.5 mg triamterene and 25 mg hydrochlorothiazide 

75 mg/50 mg = 75 mg triamterene and 50 mg hydrochlorothiazide

The usual dose of Triamterene and Hydrochlorothiazide 37.5 mg/25 mg is one or two tablets daily, given as a single dose, with appropriate monitoring of serum potassium (see WARNINGS). The usual dose of Triamterene and Hydrochlorothiazide 75 mg/50 mg is one tablet daily, with appropriate monitoring of serum potassium (see WARNINGS). There is no experience with the use of more than one 75 mg/50 mg tablet daily or more than two 37.5 mg/25 mg tablets daily. Clinical experience with the administration of two 37.5 mg/25 mg tablets daily in divided doses (rather than as a single dose) suggests an increased risk of electrolyte imbalance and renal dysfunction. 

Patients receiving 50 mg of hydrochlorothiazide who become hypokalemic may be transferred to 75 mg/50 mg product directly. Patients receiving 25 mg hydrochlorothiazide who become hypokalemic may be transferred to a 37.5 mg triamterene/25 mg hydrochlorothiazide directly. 

In patients requiring hydrochlorothiazide therapy and in whom hypokalemia cannot be risked, therapy may be initiated with 37.5 mg/25 mg of triamterene and hydrochlorothiazide. If an optimal blood pressure response is not obtained with 37.5 mg/25 mg of triamterene and hydrochlorothiazide, the dose should be increased to two 37.5 mg/25 mg tablets daily as a single dose, or one 75 mg/50 mg tablet daily. If blood pressure still is not controlled, another antihypertensive agent may be added (see PRECAUTIONS, Drug Interactions). 

Clinical studies have shown that patients taking less bioavailable formulations of triamterene and hydrochlorothiazide in daily doses of 25 mg to 50 mg hydrochlorothiazide and 50 mg to 100 mg triamterene may be safely changed to one 37.5 mg/25 mg of triamterene and hydrochlorothiazide daily. All patients changed from less bioavailable formulations to triamterene and hydrochlorothiazide should be monitored clinically and for serum potassium after the transfer.
Liquid crystalline (meth)acrylates of the invention include at least three rigid rod-like moieties. One of these moieties is comprised between the (meth)acrylate rests and further two moieties are bonded as side chains. The liquid crystalline (meth)acrylates polymerizable using redox initiators and/or photo intiators. The (meth)acrylates of the invention polymerize quantitative and with very low volume shrinkage of less than 2.5 percent. The invention provides a polymerizable compound within the scope of general formula (I).  These compounds are used in dental compositions and methods of use thereof.
The invention discloses a preparation and activity detection method for duck leukocyte interferon for treating duck viral disease. Duck source newcastle disease virus is used as an inducer for inducing healthy duck leukocyte. The method comprises the processes of raw material preparation, mixing, water bath stirring culture, centrifugation and harvesting, virus inactivation, sterilization, anti-virus activity detection and the like. The fresh complete blood of a duck is successfully used as a raw material, the preparation process is simple and convenient, and the product quality is reliable. After the duck leukocyte interferon is used for a duck body, the duck leukocyte interferon has the characteristics of good treatment effect, safety, reliability, no toxic or side effect and the like. The duck leukocyte interferon for broad spectrum virus resistance has the function of treating the viral diseases such as duck plague, duck viral hepatitis, duck source newcastle disease, duck source egg drop syndrome and the like. The duck leukocyte interferon is used for the animal body, and has the advantages of good treatment effect, safety, reliability, low using amount, no toxic or side effect, low cost and the like.
PURPOSE:To determine the activity of dried powder of green mussel extremely easily and surely, by administering the powder to a caudated animal, measuring the rate of bleeding, calculating the suppressing ratio of bleeding, and using the ratio as the titer. CONSTITUTION:A definite amount of dried green mussel powder is suspended in physiological saline water, and administered to a caudated animal such as mouse e.g. by intravenous injection. After a definite time, the end of the tail is cut, the blood is collected for a definite time (e.g. 1min), and the amount of the blood is measured as the absorbance by an absorption photometer. As a control, similar procedure is repeated using physiological saline water in place of the suspension of dried green mussel powder. The decrease of the bleeding from the tail is calculated from the absorbance data of the above experiments, and is used as the activity of the dried green mussel powder. The green mussel is a bivalve living off the coast of New Zealand, and has pharmacological effect to arthralgia, etc.
A compsn. for permanent waving of hair, based on a mercaptocarboxylic acid ester contains an N-acylcysteamine of formula HS-CH2CH2-NH-COR. R=1-10C alkyl. ADVANTAGE - The compsn. has no unpleasant smell, and gives uniform shaping of the hair right to the tips, without curling damaged tips. The ester and amine have a synergistic effect. The time is reduced to 15-20 mins. at 30-55 deg.C, or easily waved hair can be treated in 20 mins. without heating, or larger curlers can be used.
Procedure for the preparation of a penicillin of antibacterial activity of formula (I), where square r is hydrogen, a pharmaceutically acceptable salting ion or a radical ester hydrolizable and high elevated to 1 is hydrogen, a pharmaceutically acceptable salting ion or a radical ester former pharmaceutically acceptable. A compound of formula (II) is reactioned, where r ax is a hydrogen or a blocking group of carboxyl with a N-acrylic derivative of a formula (III) acid, where it is raised and is a blocking group of carboxyll or a group r elevated to 1 yr elevated az is hydrogen or a group of blocking the hydroxyl. If it is necessary, separate any silyl or phosphorilo group by hydrolysis or alcoholisis, as well as a carboxyl or hydroxyl blocking group. You can convert the product in a salt or in a stere of the same. It is used in the treatment of infections in animals, including man and avian cattle, caused by a wide variety of gram-negative organisms. * formula * e (Machine-translation by Google Translate, not legally binding)